{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:10:35Z","timestamp":1780477835724,"version":"3.54.1"},"reference-count":38,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Glecaprevir\/pibrentasvir (GLE\/PIB), despite being a highly costly medication, is considered a cost-effective approach compared with sofosbuvir\/velpatasvir (SOF\/VEL) and sofosbuvir\/daclatasvir (SOF\/DCV) in the treatment of hepatitis C virus (HCV) infection. No study has evaluated the effect of GLE\/PIB\u2019s introduction into Iran\u2019s drug list from a health policy perspective and estimated the budgetary impact change. Therefore, this study was conducted to analyse the fiscal effect of the introduction of GLE\/PIB into Iran\u2019s drug list.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Budget impact analysis. The assumptions and costs of including GLE\/PIB in Iran\u2019s drug list for the treatment of patients with hepatitis C were derived from a conducted cost-effectiveness analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>National level. In this study, the budgetary changes in Iran\u2019s pharmaceutical market and health system, from the Ministry of Health\u2019s perspective, have been estimated for a 5-year time horizon following the introduction of GLE\/PIB in the country.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Based on the results obtained from the budget impact model, currently, 4112 patients are receiving SOF\/DCV and SOF\/VEL therapeutic regimens, which is expected to decrease to 1093 in 2029 owing to the affordability of medications and a 50% estimated market share for GLE\/PIB. According to the results, with the introduction of GLE\/PIB into the market and assuming a market share of 10% in the first year, growing to 50% by the fifth year, the healthcare system costs will increase by approximately $0.61, $1.77, $3.86, $7.45 and $13.51\u2009million over the next 5 years, respectively. Additionally, based on the drug\u2019s selling price, there will be a 468% increase in hepatitis C drug market costs after 5 years, resulting in an overall budget increase of approximately 0.13% for Iran\u2019s pharmaceutical market. According to the sensitivity analysis, a 20% reduction in chronic hepatitis C (CHC) costs could decrease the projected increase in health sector costs from $13.51\u2009million (an 18.84% increase) to $10.52\u2009million (an 18.16% increase). Conversely, a 20% rise in CHC costs would raise those costs to $16.49\u2009million (a 19.31% increase).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Considering the high price of the GLE\/PIB compared with the available options in Iran, with the introduction of GLE\/PIB into Iran\u2019s drug list, insurance coverage and appropriate allocation of necessary resources, a reduction in the cost burden because of hepatitis C treatment is expected for individuals and households. Additionally, with a well-regulated market share of existing medications, the optimal treatment choice for patients will be feasible.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-092359","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:40:26Z","timestamp":1757652026000},"page":"e092359","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Budget impact analysis of glecaprevir\/pibrentasvir treatment for hepatitis C in Iran: a modelling study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-471X","authenticated-orcid":false,"given":"Mojtaba","family":"Jafari","sequence":"first","affiliation":[{"name":"Student Research Commite, Baqiyatallah University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"},{"name":"Health Human Resources Research Center, Department of Health Economics, School of Health Management and Information Sciences, Shiraz University of Medical Sciences Shiraz Transplant Research Center, Shiraz, Iran (the Islamic Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-4646","authenticated-orcid":false,"given":"Parisa","family":"Mehdizadeh","sequence":"additional","affiliation":[{"name":"Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-5502","authenticated-orcid":false,"given":"Khosro","family":"Keshavarz","sequence":"additional","affiliation":[{"name":"Health Human Resources Research Center, School of Health Managementand Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran, Iran (the Islamic Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-9853","authenticated-orcid":false,"given":"Ehsan","family":"Teymourzadeh","sequence":"additional","affiliation":[{"name":"Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-3268","authenticated-orcid":false,"given":"Mohammad Ali","family":"Abyazi","sequence":"additional","affiliation":[{"name":"Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Clinical sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1783-119X","authenticated-orcid":false,"given":"Parsa","family":"Gholamreza Shirazi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran (the Islamic Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2025091121402199000_15.9.e092359.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"2025091121402199000_15.9.e092359.2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bpg.2012.09.012","article-title":"Public health issues of hepatitis C virus infection","volume":"26","author":"Papatheodoridis","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025091121402199000_15.9.e092359.3","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13316"},{"key":"2025091121402199000_15.9.e092359.4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2017.03.012","article-title":"Economic Burden of Hepatitis C Infection","volume":"21","author":"Stepanova","year":"2017","journal-title":"Clin Liver Dis"},{"key":"2025091121402199000_15.9.e092359.5","article-title":"Seroprevalence of HCV antibody among patients with beta-thalassemia major in Amirkola Thalassemia Center, Iran","volume":"6","author":"Tamaddoni","year":"2007","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"2025091121402199000_15.9.e092359.6","first-page":"47","article-title":"Hepatitis C Infection in Iran; A Review Article","volume":"4","author":"Alavian","year":"2009","journal-title":"Arch Clin Infect Dis"},{"key":"2025091121402199000_15.9.e092359.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18296-9","article-title":"The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses","volume":"8","author":"Mahmud","year":"2018","journal-title":"Sci Rep"},{"key":"2025091121402199000_15.9.e092359.8","first-page":"1575","article-title":"The Estimation of Economic Burden of Hepatitis C Virus Infection in Iran","volume":"47","author":"Mohammadzadeh","year":"2018","journal-title":"Iran J Public Health"},{"key":"2025091121402199000_15.9.e092359.9","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"2025091121402199000_15.9.e092359.10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12325-019-01166-3","article-title":"A Cost-Effectiveness Analysis of Glecaprevir\/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan","volume":"37","author":"Kawaguchi","year":"2020","journal-title":"Adv Ther"},{"key":"2025091121402199000_15.9.e092359.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1403619"},{"key":"2025091121402199000_15.9.e092359.12","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.25540","article-title":"Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?","volume":"14","author":"Pourhoseingholi","year":"2014","journal-title":"Hepat Mon"},{"key":"2025091121402199000_15.9.e092359.13","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon118646","article-title":"Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C","volume":"21","author":"Goudarzi","year":"2021","journal-title":"Hepat Mon"},{"key":"2025091121402199000_15.9.e092359.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058757","article-title":"Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study","volume":"12","author":"Tasavon Gholamhoseini","year":"2022","journal-title":"BMJ Open"},{"key":"2025091121402199000_15.9.e092359.15","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0594-2019","article-title":"Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil","volume":"53","author":"Ferreira","year":"2020","journal-title":"Rev Soc Bras Med Trop"},{"key":"2025091121402199000_15.9.e092359.16","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2015.1100356"},{"key":"2025091121402199000_15.9.e092359.17","first-page":"1105","article-title":"\u201cBudget impact analyses\u201d: a practical policy making tool for drug reimbursement decisions","volume":"13","author":"Jamshidi","year":"2014","journal-title":"Iran J Pharm Res"},{"key":"2025091121402199000_15.9.e092359.18","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1114560","article-title":"Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options","volume":"11","author":"Azzeri","year":"2023","journal-title":"Front Public Health"},{"key":"2025091121402199000_15.9.e092359.19","first-page":"172","article-title":"Budget Impact Analysis of HCV Patients\u2019 Pathway: Past, Present and Future in the Italian Landscape","volume":"6","author":"Foglia","year":"2022","journal-title":"J Dig Dis Hepatol"},{"key":"2025091121402199000_15.9.e092359.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.09.958","article-title":"5 Year and Long-Term Budget Impact Analysis of New Hepatitis C Therapies from A Payer Perspective in Switzerland","volume":"19","author":"Schnyder","year":"2016","journal-title":"Value Health"},{"key":"2025091121402199000_15.9.e092359.21","unstructured":"Publicbi . Available: https:\/\/publicbi.fda.gov.ir"},{"key":"2025091121402199000_15.9.e092359.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.12.011"},{"key":"2025091121402199000_15.9.e092359.23","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.37094","article-title":"A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection","volume":"18","author":"Alavian","year":"2016","journal-title":"Iran Red Crescent Med J"},{"key":"2025091121402199000_15.9.e092359.24","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.37435","article-title":"A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model","volume":"16","author":"Keshavarz","year":"2016","journal-title":"Hepat Mon"},{"key":"2025091121402199000_15.9.e092359.25","doi-asserted-by":"crossref","first-page":"10313","DOI":"10.21037\/apm-21-863","article-title":"Cost-effectiveness analysis of glecaprevir\/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2025091121402199000_15.9.e092359.26","unstructured":"Excel file. n.d. Available: https:\/\/amar.org.ir\/Portals\/0\/Statistics\/2302n220211402_v10-14031017-14031019162130.xlsx"},{"key":"2025091121402199000_15.9.e092359.27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40258-020-00623-3","article-title":"Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C","volume":"19","author":"Chen","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"2025091121402199000_15.9.e092359.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237582","article-title":"Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting","volume":"15","author":"Yen","year":"2020","journal-title":"PLoS One"},{"key":"2025091121402199000_15.9.e092359.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229517","article-title":"Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand","volume":"15","author":"Sirinawasatien","year":"2020","journal-title":"PLoS ONE"},{"key":"2025091121402199000_15.9.e092359.30","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.81a.13155"},{"key":"2025091121402199000_15.9.e092359.31","unstructured":"World Bank . World development indicator. 2023. Available: https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP?locations=IR"},{"key":"2025091121402199000_15.9.e092359.32","unstructured":"IRC . Available: https:\/\/irc.fda.gov.ir\/nfi"},{"key":"2025091121402199000_15.9.e092359.33","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1016\/S2468-2667(22)00119-0","article-title":"The role of low-income and middle-income country prisons in eliminating hepatitis C","volume":"7","author":"Akiyama","year":"2022","journal-title":"Lancet Public Health"},{"key":"2025091121402199000_15.9.e092359.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2014.11.003"},{"key":"2025091121402199000_15.9.e092359.35","doi-asserted-by":"crossref","first-page":"105412","DOI":"10.1016\/j.meegid.2023.105412","article-title":"Sub-genotypes of hepatitis C virus in the Middle East and North Africa: Patterns of distribution and temporal changes","volume":"109","author":"Athamneh","year":"2023","journal-title":"Infect Genet Evol"},{"key":"2025091121402199000_15.9.e092359.36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091121402199000_15.9.e092359.37","unstructured":"World Health Organization . Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 2021. Available: https:\/\/www.who.int\/publications-detail-redirect\/9789240027077 [Accessed 16 Dec 2023]."},{"key":"2025091121402199000_15.9.e092359.38","unstructured":"AMAR . Available: https:\/\/amar.org.ir"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-092359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:40:31Z","timestamp":1757652031000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-092359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2024-092359"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-092359","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}